Related Experiment Video
Updated: Sep 27, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Targeting cancer's sweet spot: UGP2 as a therapeutic vulnerability
Sunghoon Kim1,2, Andrew Wolfe3,4, Sung Eun Kim1,2
1Department of Biosystems and Biomedical Sciences, College of Health Sciences, Korea University, Seoul, Republic of Korea.
Abstract:
Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.
Insights
UDP-glucose pyrophosphorylase 2 (UGP2) is crucial for cancer growth by driving UDP-glucose production and regulating metabolic processes. Understanding UGP2
Area of Science:
- Biochemistry
- Cancer Biology
- Metabolic Pathways
Background:
- Metabolic reprogramming is a hallmark of cancer, presenting potential therapeutic vulnerabilities.
- The enzyme UDP-glucose pyrophosphorylase 2 (UGP2) is essential for synthesizing UDP-glucose, a key metabolite.
Purpose of the Study:
- To elucidate the role of UGP2 in cancer cell metabolism and growth.
- To investigate UGP2's contribution to cancer-associated metabolic reprogramming.
Main Methods:
- Enzyme activity assays to measure UGP2 function.
- Metabolomic analysis to profile cellular metabolic changes.
- Cancer cell proliferation and growth assays.
Main Results:
- UGP2 activity was found to be critical for sustaining high rates of UDP-glucose production in cancer cells.
- Inhibition or depletion of UGP2 led to significant reductions in cancer cell growth and metabolic flux.
- UGP2 was identified as a key regulator of specific metabolic pathways essential for tumor progression.
Conclusions:
- UGP2 is a critical enzyme in cancer metabolism, driving UDP-glucose synthesis and supporting tumor growth.
- Targeting UGP2 represents a potential therapeutic strategy for exploiting metabolic vulnerabilities in cancer.
- Further research into UGP2's regulatory mechanisms could uncover new avenues for cancer treatment.
More Related Videos
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...